Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Getting Overdose Antidote with Painkillers May Cut ER Visits

By Lauran Neergaard, AP Medical Writer | June 28, 2016

WASHINGTON (AP) — Overdoses don’t happen just to heroin addicts—patients who legally use strong painkillers called opioids are at risk in the nation’s epidemic, too. A new study says when patients were prescribed an overdose antidote along with those medications, they made fewer painkiller-related visits to the emergency room.

Hospitals and first responders have long used the antidote naloxone to revive people who’ve stopped breathing because of an opioid overdose. Increasingly, take-home doses also are given to friends or family of people struggling with substance abuse to keep on hand in case of emergency.

Monday’s study went a step further—to see if the take-home antidote idea also could work for patients with chronic pain who may not realize they could accidentally get into trouble with prescription painkillers such as Oxycontin, Vicodin and others.

“Patients don’t see themselves at risk for overdose,” said lead researcher Dr. Phillip Coffin of the San Francisco Department of Public Health. “We’re prescribing naloxone for risky drugs, not risky patients.”

The Centers for Disease Control and Prevention says between 1999 and 2014, more than 165,000 people in the U.S. died of overdoses related to opioid pain medications. Taking too much, either deliberately or accidentally, isn’t the only worry. Other illnesses and medications sometimes can make a usually tolerated opioid dose risky.

San Francisco already had seen a drop in heroin deaths from targeted naloxone distribution. On the prescription painkiller side, Coffin’s team told six primary care clinics run by the health department to add a naloxone prescription for all patients with chronic pain who were taking long-term opioids for relief. The clinics serve publicly insured or uninsured patients. To help ensure they listened, providers were urged to say the antidote was for “bad reactions” to painkillers rather than using the word “overdose.”

About 38 percent of the 1,985 eligible patients received a prescription for the antidote and were taught to use it, researchers reported in Annals of Internal Medicine. Patients were more likely to receive naloxone if they used a particularly high dose of opioids or had a prior painkiller-related ER visit—such as for overdoses or sedation-caused falls.

Over the next year, patients prescribed just-in-case naloxone had 47 percent fewer painkiller-related ER visits as their counterparts who didn’t get that prescription, Coffin found.

The study doesn’t prove naloxone helped, and there were too few deaths to know if the approach could save lives. Two of the five opioid-related deaths were among patients prescribed naloxone. A survey found 5 percent of the naloxone recipients had an overdose reversed when they took the antidote that had been prescribed, Coffin said.

But he said it’s possible the shock effect of being given an antidote to your medication makes people heed side effects and take better steps to avoid them: “Instead of safety messaging going in one ear and out the other, it really stuck.”

New CDC guidelines say doctors can consider co-prescribing naloxone with painkillers for patients deemed at high risk.

Monday’s study suggests the antidote approach is feasible for primary care providers, and “the results are encouraging,” Boston University addiction specialists Alexander Walley and Traci Green wrote in an accompanying editorial. They weren’t involved in the research.

“It provides a practical starting point for future, broader implementation efforts,” they concluded.

The drug can cost $80 or more, but Coffin said it often is covered by public insurance programs and is far cheaper than an ER visit.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE